Supplement
Beta Glucan
Discover the science-backed potential of beta glucan as an adjunct in cancer therapy. This post delves into the latest research
Click 
Hydrogen gas (H₂), sometimes referred to as “Brown Gas” when generated by electrolysis, is gaining attention in the field of metabolic therapy for its potential anti-cancer properties.
Below is a comprehensive overview of the current scientific understanding, clinical evidence, and proposed mechanisms by which H₂ may exert anti-cancer effects.
Hydrogen gas is a unique gas signalling molecule with several biological activities relevant to cancer therapy:
Antioxidant Effects: H₂ selectively neutralises harmful reactive oxygen species (ROS), particularly hydroxyl radicals, without disturbing beneficial ROS needed for normal cell signalling67.
Anti-Inflammatory Action: H₂ can suppress pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukins, which are implicated in cancer initiation and progression17.
Regulation of Apoptosis: Hydrogen gas can modulate apoptosis (programmed cell death), either protecting normal cells from chemotherapy-induced damage or promoting apoptosis in cancer cells by influencing key proteins like Bax and Bcl-21.
Immunomodulation: H₂ enhances the activity of natural killer (NK) cells and reduces chronic inflammation, both of which are important for immune surveillance and tumour control7.
Cellular Signalling: H₂ affects pathways such as PI3K/AKT and MAPK, which are crucial for cell proliferation, survival, and apoptosis, thereby inhibiting tumour growth and promoting cancer cell death7.
Patient Studies: The largest real-world study to date followed 82 patients with stage III and IV cancers who received hydrogen inhalation therapy. Results showed:
A disease control rate of 57.5% (complete or partial remission) in patients with visible tumours, with better outcomes in stage III (83%) than stage IV (47.7%) patients234.
Significant improvements in quality of life, including reductions in fatigue, insomnia, anorexia, and pain23.
Decreases in tumour markers within weeks in over a third of patients, especially those with lung cancer23.
No serious adverse effects; minor reactions like drowsiness or agitation resolved spontaneously236.
Case Reports: Individual cases, such as metastatic gallbladder cancer, have shown tumour shrinkage, improved blood markers, and enhanced general health following hydrogen therapy, even when standard treatments had failed6.
Laboratory Studies: In vitro and animal studies have demonstrated that hydrogen gas can:
Combination Therapy: Clinical trials indicate that hydrogen gas can be safely combined with chemotherapy and immunotherapy, often reducing side effects and enhancing overall survival and progression-free survival45.
Quality of Life and Safety: Hydrogen therapy is generally well-tolerated, with a favourable safety profile and no reported haematological toxicity2346.
Research Stage: While the evidence is promising, most studies are small or observational. Larger, randomised clinical trials are needed to confirm efficacy, determine optimal dosages, and establish long-term safety47.
Mechanisms: Although several anti-cancer mechanisms have been proposed, further research is required to fully elucidate how hydrogen gas interacts with cancer biology67.
| Aspect | Findings | Evidence Type |
|---|---|---|
| Tumour Control | Disease control rate up to 83% in stage III, 47.7% in stage IV cancers | Clinical study234 |
| Quality of Life | Significant improvements in fatigue, pain, appetite, sleep | Clinical study23 |
| Tumour Shrinkage | Documented in case reports, especially in lung and gallbladder cancers | Case report6 |
| Side Effects | Minimal, mainly mild and transient (drowsiness, agitation) | Clinical study236 |
| Mechanisms | Antioxidant, anti-inflammatory, immunomodulatory, apoptosis regulation, signalling modulation | Review/lab studies147 |
| Compatibility | Can be combined with chemotherapy/radiotherapy for enhanced effect and reduced toxicity | Clinical trials45 |
Hydrogen gas (H₂/Brown Gas) shows significant promise as both a stand-alone and adjunctive therapy for cancer. It appears to control tumour progression, improve quality of life, and reduce treatment-related side effects, with a strong safety profile. While further research is needed, especially large-scale clinical trials, H₂ therapy represents a novel and potentially revolutionary approach in metabolic cancer therapy123467.
Hydrogen gas (H₂) therapy has demonstrated a strong safety profile in clinical studies, with specific dosage parameters emerging as potentially safe and effective.
While research is ongoing, current evidence suggests the following:
Inhalation of 2.4% H₂ in air has been rigorously tested in healthy adults over 24-hour periods, showing no clinically significant adverse effects on respiratory, neurological, or organ function4. This concentration is widely used in clinical trials for cancer and other conditions.
Lower concentrations (1–2%) are frequently employed in shorter-duration studies, such as adjuvant therapy during chemotherapy or radiotherapy, with similar safety outcomes16.
Delivery Method: Inhalation remains the most studied and practical approach, allowing precise control over dosage. Other methods (e.g., hydrogen-rich water) lack standardised dosing protocols.
Duration: Prolonged exposure (up to 24 hours) at 2.4% H₂ has been safely tolerated4, but optimal treatment durations for cancer patients are still under investigation.
Combination Therapies: When used alongside chemotherapy or radiotherapy, H₂ dosages are typically adjusted to avoid interference with treatment efficacy, often administered before or after sessions17.
No long-term toxicity data exists, though H₂’s rapid exhalation and selective antioxidant properties minimise overdose risks6.
Contraindications include bacterial overgrowth conditions (e.g., small intestinal bacterial overgrowth), where H₂ may exacerbate symptoms3.
Current protocols favour 2–2.4% H₂ inhalation for 1–2 hours daily as a conservative starting point, pending further large-scale trials to refine dosages for specific cancer types and stages146.
Brain Cancer, Cervical Cancer, Colorectal Cancer, Oesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Hydrogen gas (H₂) therapy, at therapeutic doses used for cancer (typically 1–3 hours daily inhalation at concentrations up to 2.4%, with some studies using higher concentrations or longer durations), has demonstrated a strong safety profile in both clinical trials and observational studies.
The vast majority of studies report no significant adverse effects attributable to hydrogen gas inhalation, even when combined with chemotherapy or radiotherapy2357.
Mild, transient reactions such as drowsiness or agitation have been occasionally observed, but these resolved spontaneously and did not require intervention5.
No haematological toxicity or organ damage has been reported, and vital signs (blood pressure, heart rate, etc.) remained stable during and after inhalation345.
In studies comparing hydrogen therapy to placebo during chemotherapy, hydrogen was found to reduce the incidence and severity of side effects such as fatigue, liver dysfunction, and general malaise, rather than cause additional adverse effects16.
Routine monitoring in trials specifically looked for symptoms such as nosebleed, cough, chest pain, dyspnoea, nausea, vomiting, dizziness, earache, and allergic reactions; none of these were observed at therapeutic doses23.
There is currently no data on long-term toxicity, but hydrogen’s rapid exhalation and selective antioxidant action make overdose or cumulative toxicity highly unlikely7.
| Side Effect | Frequency/Severity |
|---|---|
| Drowsiness, agitation | Rare, mild, self-limiting |
| Haematological toxicity | None observed |
| Organ dysfunction | None observed |
| Allergic reactions | None observed |
| Other (nausea, dizziness, etc.) | None observed |
| Long-term toxicity | No data, but considered unlikely |
Hydrogen gas therapy, at doses used in cancer treatment, is very well tolerated with minimal and transient side effects. Most studies suggest it may actually reduce the adverse effects of conventional cancer therapies, rather than add to them.
Hydrogen therapy has been tested in combination with other therapies.
Clinical studies and trials have combined hydrogen (H₂) with:
Chemotherapy (e.g., XELOX/CapeOX, 5-FU, mFOLFOX6)
Immunotherapy (e.g., Nivolumab)
Targeted therapy
Radiotherapy
These studies have shown that hydrogen can enhance overall survival, prolong progression-free survival, reduce the side effects of conventional treatments, and improve quality of life, without diminishing the anti-tumour effects of the primary therapies12571316.
At therapeutic levels (typically daily inhalation sessions of 1–3 hours or hydrogen-rich water at clinically studied concentrations), hydrogen therapy has demonstrated a consistent and meaningful positive impact on quality of life for cancer patients.
Reduction in Fatigue, Pain, Insomnia, and Anorexia: Multiple clinical studies and real-world evidence show significant improvements in these symptoms after just 4 weeks of hydrogen therapy, with nearly half of patients reporting better physical condition. The greatest improvements were observed in lung cancer patients, while the least were seen in pancreatic and gynaecological cancers25.
Improved Physical Fitness and Function: After 3 months of hydrogen inhalation, 42% of patients showed improved physical condition, and 34% maintained stability. This was measured using standard physical fitness scoring systems. Notably, both hydrogen monotherapy and combination therapy with conventional treatments produced similar improvements25.
Alleviation of Chemotherapy and Radiotherapy Side Effects: Hydrogen’s antioxidant and anti-inflammatory properties help protect against the adverse effects of chemotherapy and radiotherapy, such as liver and kidney toxicity, loss of appetite, taste disturbances, and general malaise. Studies report that hydrogen therapy can prevent or reverse these side effects without impairing the anti-tumour efficacy of standard treatments1346.
Emotional and Mental Health Benefits: Patients receiving hydrogen therapy reported better overall well-being, with improvements in both mental and physical health domains35.
No Significant Adverse Effects: Therapeutic hydrogen therapy is well tolerated, with only minor, transient side effects such as mild drowsiness or agitation, and no evidence of haematological or organ toxicity256.
| Benefit | Evidence/Notes |
|---|---|
| Fatigue, pain, insomnia, anorexia reduced | Consistent improvement within 4 weeks25 |
| Physical fitness and function improved | 42% improved, 34% stable after 3 months25 |
| Chemotherapy/radiotherapy side effects eased | Less liver/kidney damage, better appetite, less malaise1346 |
| Mental and emotional well-being enhanced | Reported by patients in clinical and observational studies35 |
| Safety/tolerability | No serious side effects, minor reactions rare256 |
Hydrogen therapy at therapeutic levels can significantly improve the quality of life for cancer patients, especially by reducing fatigue, pain, insomnia, and treatment-related side effects, while supporting physical and mental well-being. These benefits are seen across a range of cancer types and are achieved with a strong safety profile251346.
We’ve done our best to include as much information as possible for this supplement.
If you have any other questions, please send us a message or join our Skool Group and ask our knowledgeable and friendly community.
“H2 Brown Gas” does not have any regulatory status or approved procurement channels within the medical field.
No specific patient demographic has been definitively determined as most likely to benefit from hydrogen (H₂) therapy in cancer. Clinical studies have included a wide range of adult patients—both male and female, and across various ages—primarily with advanced-stage cancers such as non-small cell lung cancer. Outcomes did not significantly differ according to age, sex, or most other baseline characteristics145.
However, there is some indication that patients with certain tumour-gene mutations (such as EGFR mutations in lung cancer) may have been more prevalent in groups receiving targeted therapy alongside H₂, but this has not been established as a decisive predictive factor for benefit1.
In summary, current research does not identify a particular demographic (by age, sex, or genetic profile) that benefits most from H₂ therapy; rather, the therapy appears broadly applicable among adults with advanced cancer, especially those seeking to control tumour progression or alleviate side effects from conventional treatments1413.
No specific resistance markers have been identified that directly affect hydrogen (H₂) therapy’s efficacy in cancer. However, clinical studies note variable responses linked to tumour type and stage:
Lower Efficacy in Certain Cancers: Pancreatic and hepatic cancers showed reduced disease control rates (20–47.7%) compared to lung cancer (79%)35.
Stage Dependency: Stage IV cancers had lower response rates (47.7%) than stage III (83%)35.
Pathway Involvement: H₂’s effects on ROS, NF-κB, and PI3K/AKT pathways are critical, but no mutations in these pathways have been validated as resistance markers124.
Summary:
While tumour biology influences outcomes, no definitive molecular or genetic resistance markers have been established. Research continues to explore factors affecting H₂’s anti-cancer activity.
Hydrogen gas has been extensively studied in pre-clinical models (cell cultures and animal studies) across multiple cancer types.
Below is a summary of key findings:
Colorectal Cancer
Endometrial Cancer
Hydrogen-rich water (HRW) induced pyroptosis (inflammatory cell death) via NLRP3 inflammasome activation2.
Glioblastoma
Reduced glioma stem-like cell development and inhibited migration/invasion in vitro and in vivo2.
Gastric Cancer
Suppressed tumour growth by downregulating lncRNA MALAT1/EZH2 and upregulating miR-124-3p2.
Cervical Cancer
Promoted apoptosis and reduced oxidative stress in cell lines and xenograft models2.
Lung Cancer
Ovarian Cancer
Oesophageal Squamous Cell Carcinoma
H₂-silica nanoparticles induced mitochondrial apoptosis and cell cycle arrest (G2/M phase)3.
Melanoma
Hydrogen inhalation and inulin fermentation both reduced tumour growth in mice via enhanced immunosurveillance1.
Apoptosis Induction: Triggered mitochondrial apoptotic pathways23.
ROS Modulation: Selectively neutralised hydroxyl radicals while increasing beneficial H₂O₂ in cancer cells25.
Immune Activation: Enhanced CD8+ T cell function and macrophage phagocytosis12.
Gene/Protein Regulation: Suppressed SMC3, CD47, and MALAT1; upregulated miR-124-3p23.
Anti-Angiogenesis: Reduced CD34 expression in ovarian cancer models4.
| Cancer Type | Model | Key Outcome | Mechanism | Source |
|---|---|---|---|---|
| Colorectal | Mice xenografts | Tumour growth inhibition | Enhanced 5-FU efficacy | 12 |
| Ovarian | Hs38.T/PA-1 cells | Reduced proliferation/invasion | Anti-angiogenesis (CD34↓) | 24 |
| Lung | In vitro | Cell viability↓, migration↓ | SMC3 suppression | 23 |
| Oesophageal squamous cell | KYSE-70 cells | Apoptosis↑, cell cycle arrest (G2/M) | H₂O2 accumulation | 3 |
| Glioblastoma | Mouse models | Stem-like cell inhibition | Reduced colony formation | 2 |
Pre-clinical trials demonstrate hydrogen gas’s broad anti-cancer activity across diverse tumour types, primarily through apoptosis induction, ROS modulation, and immune activation. These findings support its potential as a safe adjunct to conventional therapies, though further research is needed to optimise dosing and delivery methods.
Hydrogen (H₂) therapy is currently part of ongoing clinical trials for cancer and other conditions.
Cancer Trials:
CAM-H2 (radiopharmaceutical) is in a Phase I/II clinical trial for HER2-positive metastatic breast and gastric/gastro-oesophageal cancer (NCT04467515). This trial is actively recruiting and is evaluating safety, tumour uptake, retention, and early signs of anti-tumour activity2.
Multiple small clinical trials and case series have tested hydrogen gas (inhalation or hydrogen-rich water) in cancers such as non-small cell lung cancer, liver cancer, and others, generally at early phases (Phase I/II)1356.
Other Conditions:
Trials are also ongoing for hydrogen’s feasibility and safety in non-cancer conditions (e.g., the Hydrogen FAST Trial for ECPR), currently in an early phase4.
| Cancer Type/Condition | Trial Phase | Status |
|---|---|---|
| HER2-positive metastatic cancer (CAM-H2) | Phase I/II | Active/Recruiting2 |
| NSCLC, liver, other cancers (various H₂) | Phase I/II | Completed/Ongoing1356 |
| Non-cancer (ECPR, etc.) | Early phase | Recruiting4 |
Hydrogen therapy is actively being studied in Phase I/II clinical trials for cancer, with some trials recruiting and others completed or ongoing in early phases. There are no reports of Phase III cancer trials for hydrogen gas therapy as of April 2025.
For the latest information, visit Clinical Trials on H2 Brown Gas.
No specific genetic markers have been definitively identified that directly influence the efficacy of hydrogen (H₂) therapy. However, research highlights several pathways and gene-related mechanisms through which H₂ may exert its effects:
Nrf2/HO-1 Pathway: H₂ activates this antioxidant pathway, which regulates oxidative stress responses2912. Genetic variations in Nrf2 could theoretically influence therapeutic outcomes, though this remains unconfirmed.
Ca²⁺-Dependent Signaling: H₂ modulates genes like TNF-α, IL-8, and transcription factors (CREB, NFAT) via oxidised phospholipid-mediated Ca²⁺ signaling610. Variants in these genes might affect response, but no studies have directly linked them to H₂ efficacy.
Autophagy and Senescence: H₂ inhibits excessive autophagy and reduces markers of cellular aging (e.g., p53, p21)25, though no genetic predictors for these interactions are known.
In summary, while H₂ influences gene expression in pathways critical to oxidative stress, inflammation, and cellular repair, no validated genetic markers currently predict its efficacy. Further research is needed to explore potential genetic determinants61012.
Discover the science-backed potential of beta glucan as an adjunct in cancer therapy. This post delves into the latest research
Explore the latest scientific insights into vitamin K2 and its promising role in cancer therapy. In this comprehensive blog post,
For centuries, Ayurvedic healers have harnessed Oroxylum indicum—the “midnight horror” tree—for its medicinal prowess. Modern science now validates its ancient reputation,
Website designed in collaboration with Simon Lown for Metabolic Therapy Ltd
Apoptosis, or programmed cell death, is a natural process where cells self-destruct when they are damaged or no longer needed. This is crucial for maintaining healthy tissues and preventing diseases like cancer.
Drugs and supplements that induce apoptosis help eliminate cancerous cells by triggering this self-destruct mechanism, ensuring that harmful cells are removed without damaging surrounding healthy tissue.
Understanding and harnessing apoptosis is vital in the fight against cancer, as it targets the root cause of the disease at the cellular level.
Cell proliferation is the process by which cells grow and divide to produce more cells. While this is essential for growth and healing, uncontrolled cell proliferation can lead to cancer.
Drugs and supplements that inhibit cell proliferation help prevent the rapid multiplication of cancerous cells, slowing down or stopping the progression of the disease.
By targeting the mechanisms that drive cell division, these treatments play a vital role in controlling and potentially eradicating cancer.
Cancer cells often hijack specific biological pathways to grow and spread. Drugs and supplements that target these pathways can disrupt the cancer cell’s ability to survive and multiply.
By focusing on the unique mechanisms that cancer cells use, these treatments can be more effective and cause fewer side effects compared to traditional therapies.
Targeting specific pathways is a key strategy in precision medicine, offering a tailored approach to combat cancer at its core.
Angiogenesis is the process by which new blood vessels form, supplying nutrients and oxygen to tissues. Cancer cells exploit this process to fuel their growth and spread.
Drugs and supplements that inhibit angiogenesis can effectively starve cancer cells by blocking the formation of these new blood vessels.
By cutting off the supply lines that tumors rely on, angiogenesis inhibitors play a crucial role in controlling and potentially shrinking cancerous growths.
Immunotherapy harnesses the power of the body’s immune system to combat cancer. By boosting or restoring the immune system’s natural ability to detect and destroy cancer cells, immunotherapy offers a targeted and effective approach to treatment.
Drugs and supplements that support immunotherapy can enhance the immune response, making it more efficient at identifying and attacking cancer cells.
This innovative approach not only helps in treating cancer but also reduces the risk of recurrence, providing a powerful tool in the fight against this disease.
Inflammation is the body’s natural response to injury or infection, but chronic inflammation can contribute to the development and progression of cancer.
Drugs and supplements with anti-inflammatory properties help reduce inflammation, thereby lowering the risk of cancer and other chronic diseases.
By targeting the inflammatory processes, these treatments can help maintain a healthier cellular environment and prevent the conditions that allow cancer to thrive.
